UNSPSC 51313901: Eflumast

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3CIG2V70UB. European Medicines Agency schedules Eflumast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06470MIG. Eflumast generally arises in the molecular formula C10H8FN5O3.

UNSPSC 51313901 Eflumast, a Commodity code, covers pharmaceutical products and drug-related systems that state and local governments procure to support public health and community safety initiatives. Recent solicitations under this code show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Vendors responding to opportunities under this code must comply with FDA manufacturing requirements, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), and various insurance and compliance obligations including workers' compensation, commercial general liability coverage, and federal workplace verification standards.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing therapeutic pharmacy initiatives outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract performance commencing July 1, 2026. Vendors must work through three authorized wholesalers and meet strict pricing, EDI capability, and compliance requirements including a 3 percent administrative fee and performance penalties for violations.